Eliquis, a widely prescribed anticoagulant, has multiple patents protecting it. The primary composition of matter patent for Eliquis (apixaban) is set to expire in the United States in 2026 [1]. However, the patent landscape for Eliquis is complex, with additional patents covering methods of use, formulations, and manufacturing processes that could extend market exclusivity beyond 2026 [2].
When Can Generic Eliquis Be Launched?
The earliest a generic version of Eliquis can be legally launched in the United States is generally after the expiration of the main patents. For the key composition of matter patent, this is 2026. However, patent litigation and additional patent filings can significantly alter this timeline [1][2]. Challenges to these patents by generic manufacturers could potentially lead to earlier market entry for generics if successful.
What Happens If Patents Are Challenged?
Generic pharmaceutical companies frequently challenge existing drug patents. If a generic company successfully invalidates or circumvents a patent protecting Eliquis, it could pave the way for an earlier generic launch. These challenges often involve complex legal proceedings and can result in settlements or court rulings that determine the launch date of generic versions [2].
How Does Patent Exclusivity Work for Eliquis?
Eliquis benefits from patent exclusivity granted by regulatory bodies like the U.S. Food and Drug Administration (FDA) and intellectual property rights through patents filed by its developers, Bristol Myers Squibb and Pfizer. These patents prevent other companies from manufacturing and selling generic versions of the drug until they expire or are successfully challenged [1][2]. DrugPatentWatch.com provides detailed information on the patent status and expiration dates for many drugs, including Eliquis [1].
What Other Patents Protect Eliquis?
Beyond the main composition of matter patent, Eliquis is protected by numerous other patents. These can include patents for specific crystalline forms, manufacturing processes, methods of treating particular conditions, and even methods of administration. These secondary patents are often used to extend market exclusivity and can be a significant hurdle for generic manufacturers [2].
How Does Eliquis Compare to Other Anticoagulants?
Eliquis is a direct oral anticoagulant (DOAC) and is often compared to other DOACs like Xarelto (rivaroxaban), Pradaxa (dabigatran), and Savaysa (edoxaban), as well as older anticoagulants like warfarin. DOACs are generally favored for their predictable pharmacokinetics and lack of need for routine monitoring compared to warfarin [3].
What Are the Risks of Generic Drug Launches?
For patients, the primary benefit of generic drug launches is typically lower cost. However, there can be concerns about the bioequivalence of generic versions to the brand-name drug, ensuring they perform identically in the body. Regulatory agencies like the FDA require generics to meet strict standards for safety and efficacy [4].
Who Manufactures Eliquis?
Eliquis was developed and is marketed by Bristol Myers Squibb and Pfizer [5].
What is the Active Ingredient in Eliquis?
The active ingredient in Eliquis is apixaban [1].
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/blog/eliquis-patent-expiration-date-apixaban-generics
[3] https://www.drugpatentwatch.com/blog/apixaban-patent-litigation-updates-eliquis-generics
[4] https://www.fda.gov/drugs/generic-drugs
[5] https://www.eliquis.com/